COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.
You may also be interested in...
Two prominent former US FDA officials are a part of the president-elect’s new COVID-19 advisory board. Biden’s emphasis on scientific independence, including a commitment to publicly release vaccine trial data, could help restore public confidence in the agency and coming COVID-19 vaccines.
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
Pfizer CEO Albert Bourla said he is disappointed in the US politicization of a COVID-19 vaccine in a letter to employees. ‘We are moving at the speed of science,’ he said.